厄贝沙坦与贝那普利治疗冠心病伴高血压对患者血管内皮功能指标的影响对比

The Effect of Irbesartan and Benazepril on Coronary Artery Disease and Hypertension in Patients With Vascular Endothelial Function

目的对比厄贝沙坦与贝那普利治疗冠心病(CHD)伴高血压(EH)对患者血管内皮功能指标的影响。方法选择120例CHD伴EH患者为受试对象,随机分成研究组及对照组各60例。对照组使用贝那普利进行治疗,研究组使用厄贝沙坦进行治疗。比较治疗前及治疗1个月后两组患者血管内皮功能指标[一氧化氮(NO)、内皮素-1(ET-1)]及晨起血压[舒张压(DBP)、收缩压(SBP)]变化,并分析两组患者治疗1个月内发生药物不良反应差异。结果治疗1个月后,两组患者NO水平均较治疗前显著升高,且研究组明显高于同一时期对照组(P<0.05);两组患者ET-1水平均较治疗前显著降低,且研究组明显低于同一时间对照组(P<0.05);两组患者晨起DBP及SBP水平均较治疗前显著降低(P<0.05),两组患者DBP及SBP水平比较无统计学意义(P>0.05)。治疗1个月内,研究组干咳发生率明显低于对照组(P<0.05),其余药物不良反应情况比较均无统计学差异(P>0.05)。结论厄贝沙坦治疗CHD伴EH疗效显著,与贝那普利相当,但厄贝沙坦可显著改善CHD伴EH患者血管内皮功能水平,且安全性较贝那普利更好,对患者预后恢复有利。

Objective To compare the effects of irbesartan and benazepril on coronary artery disease(CHD)with hypertension(EH)on vascular endothelial function parameters.Methods A total of 120 patients with CHD and EH were selected as test subjects and randomly divided into a study group and a control group of 60 cases each.The control group was treated with benazepril and the study group was treated with irbesartan.The changes of vascular endothelial function indexes(NO,ET-1)and morning blood pressure(DBP,SBP)of the two groups of patients were compared before and after 1 month of treatment,and the differences in adverse drug reactions within 1 month of treatment were analyzed.Results After 1 month of treatment,the levels of NO in the two groups were significantly higher than before treatment,and the study group was significantly higher than the control group in the same period(P<0.05).The levels of ET-1 in the two groups were significantly lower than before treatment,and the study group was significantly lower than the control group at the same time(P<0.05).In the morning,the levels of DBP and SBP in the two groups were significantly lower than before treatment(P<0.05),and the levels of DBP and SBP between the two groups were not statistically significant(P>0.05).Within 1 month of treatment,the incidence of dry cough in the study group was significantly lower than that in the control group(P<0.05).There were no significant differences in other adverse drug reactions(P>0.05).Conclusion Irbesartan is effective in treating CHD with EH,which is equivalent to benazepril,but irbesartan can significantly improve the level of vascular endothelial function in patients with CHD and EH,and the safety is better than benazepril,which is beneficial to the recovery of patients'prognosis.